[Home]

Vision:


BCC Microimaging is a biotechnology company that plans to become profitable by establishing itself as a leading provider of specialized research products including photosensitive protein probes and imaging software applications. The company is focusing on developing tagged antibody reagents for cancer research as well as the detection and localization of oxidative DNA damage and its repair. Reactive oxygen species (ROS) are generated as by-products of metabolic processes in all growing cells.


Under normal conditions, cells have well developed, anti-oxidant defenses to minimize cellular damage. It has been known for some time, however, that ROS that escape anti-oxidant defenses damage the genome. Although oxidative DNA damage has been primarily associated with aging, degenerative diseases and cancer, these lesions also have an impact on the accurate transmission of genetic material at fertilization. Because of the limitations associated with current methods for evaluating DNA damage, BCC Microimaging is developing new reagents to evaluate and localize oxidative DNA damage and DNA repair in intact cells.

As a result of the recent developments in light microscopy, dye conjugated-antibodies have become critical research tools in localization studies. This fact has brought about a growing need for commercially available dye conjugated-antibodies as an efficient and cost effective way to localize or follow cellular markers by fluorescent microscopical techniques.

BCC Microimaging is pioneering methods for the direct cross-linking of small molecules (e.g., modified DNA bases) to proteins and the production of innovative photosensitive dye-conjugated antibody probes. Using these technologies anti-8-oxoguanine and anti-8-oxoguanine DNA glycosylase antibodies have been produced. 8-Oxoguanine is a modified DNA base that is mutagenic and used as a biomarker for oxidative DNA damage. 8-Oxoguanine DNA glycosylase is a major DNA repair enzyme in higher mammals including humans. Oxidative DNA damage has been related to cancer, neurodegenerative diseases and infertility.

BCC Microimaging is also developing specialized imaging software applications. Currently, BCC Microimaging has software applications for the analysis of skin pigmentation distribution and skin micro-surface topology, as well as for tracking and evaluating the movement of cells and organelles.

BCC Microimaging will continue to expand its catalog of high quality reagents and software applications for basic, clinical and industrial R&D.


8-Oxoguanine is a modified DNA base that is mutagenic and used as a biomarker for oxidative DNA damage. Oxidative DNA damage has been related to cancer, neurodegenerative diseases and infertility. BCC Microimaging is currently developing novel tagged-antibody probes for the detection and localization of antigens and subcellular structures in situ. BCC Microimaging Software division is developing specialized imaging software applications. Currently, BCC Microimaging has software applications for the analysis of skin pigmentation distribution and skin micro-surface topology, as well as for tracking and evaluating the movement of cells and organelles. BCC Microimaging will continue expanding its catalogue of high?quality reagents and software applications for basic research and industrial R&D.